Literature DB >> 30403935

Immunotherapy Combinations in Multiple Myeloma - Known Unknowns.

Nicole J Gormley1, Richard Pazdur1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30403935     DOI： 10.1056/NEJMp1803602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  20 in total

1.  An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.

Authors:  Emerson Y Chen; Vikram Raghunathan; Vinay Prasad
Journal:  JAMA Intern Med       Date:  2019-07-01       Impact factor: 21.873

2.  Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma.

Authors:  Ashraf Z Badros; Ning Ma; Aaron P Rapoport; Emily Lederer; Alexander M Lesokhin
Journal:  Blood Adv       Date:  2019-06-11

Review 3.  Dosage of anti-PD-1 monoclonal antibodies: a cardinal open question.

Authors:  M Sureda; E Calvo; J J Mata; V Escudero-Ortiz; E Martinez-Navarro; A Catalán; J Rebollo
Journal:  Clin Transl Oncol       Date:  2021-02-13       Impact factor: 3.405

Review 4.  Novel Agents in Multiple Myeloma.

Authors:  Raphaël Szalat; Nikhil C Munshi
Journal:  Cancer J       Date:  2019 Jan/Feb       Impact factor: 3.360

Review 5.  Immunotherapy in hematologic malignancies.

Authors:  R R Kansara; C Speziali
Journal:  Curr Oncol       Date:  2020-04-01       Impact factor: 3.677

Review 6.  High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.

Authors:  Chutima Kunacheewa; Elisabet E Manasanch
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-25       Impact factor: 3.020

7.  Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy.

Authors:  Erin W Meermeier; Seth J Welsh; Meaghen E Sharik; Megan T Du; Victoria M Garbitt; Daniel L Riggs; Chang-Xin Shi; Caleb K Stein; Marco Bergsagel; Bryant Chau; Matthew L Wheeler; Natalie Bezman; Feng Wang; Pavel Strop; P Leif Bergsagel; Marta Chesi
Journal:  Cancer Discov       Date:  2021-05-05       Impact factor: 39.397

8.  A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis.

Authors:  Elisabet E Manasanch; Guangchun Han; Rohit Mathur; Yun Qing; Zheng Zhang; Hans Lee; Donna M Weber; Behrang Amini; Zuzana Berkova; Karina Eterovic; Shaojun Zhang; Jianhua Zhang; Xingzhi Song; Xizeng Mao; Margaret Morgan; Lei Feng; Veera Baladandayuthapani; Andrew Futreal; Linghua Wang; Sattva S Neelapu; Robert Z Orlowski
Journal:  Blood Adv       Date:  2019-08-13

Review 9.  Immunotherapy of multiple myeloma.

Authors:  Simone A Minnie; Geoffrey R Hill
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 10.  Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.

Authors:  Bishal Gyawali; Spencer Phillips Hey; Aaron S Kesselheim
Journal:  JAMA Intern Med       Date:  2019-07-01       Impact factor: 21.873
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.